НОВАЯ СТАТЬЯ
Incorporating novel therapies into the treatment of older patients with classic hodgkin lymphoma.
Novel therapies have broadened the array of therapeutic options for older patients with cHL eligible for either curative or palliative intent therapy. Further investigation into rational combinations of these drugs, together with ongoing efforts to validate cHL-specific CGAs, aim to improve outcomes for older patients across the spectrum of fitness.
